Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Intercept (ICPT) Ocaliva's Prescribing Information Updated
by Zacks Equity Research
Intercept's (ICPT) PBC drug Ocaliva's label updated due to worsening of liver problems in some patients with cirrhosis.
Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the volatile Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BNTX, RGEN and OVID to perform well.
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss for the first quarter. Also, sales surpass expectations. However, Ocaliva's safety label remains a concern.
How Will Biotech ETFs React to These Q1 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues
by Zacks Equity Research
FATE reports a wider Q1 loss on increased R&D expenses.
Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales
by Zacks Equity Research
Ligand (LGND) reports mixed first-quarter 2021 numbers with earnings beating estimates but revenues missing the same. Stock down.
Gilead (GILD) Beats on Q1 Earnings, HIV Sales Decline
by Zacks Equity Research
Gilead (GILD) reports mixed results for the first quarter as the ongoing pandemic adversely impacted core HIV segment sales.
Gilead Sciences (GILD) Q1 Earnings Beat Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 0.97% and -5.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
TEVA Beats on Q1 Earnings and Sales, Keeps View, Stock Down
by Zacks Equity Research
TEVA beats on first-quarter earnings and sales. Sales & profits decline year over year. Keeps 2021 view.
Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News
by Zacks Equity Research
The biotech sector was in focus last week with earnings updates form Biogen (BIIB) and Amgen (AMGN), and regulatory updates from Bristol Myers (BMY), among others.
Healthcare ETFs on Radar As Q1 Earnings Unfold
by Sweta Killa
Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns.
Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More
by Zacks Equity Research
Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming first-quarter earnings call, investor focus is expected to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Editas (EDIT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.
The Zacks Analyst Blog Highlights: Visa, Exxon Mobil, SAP, Union Pacific and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, Exxon Mobil, SAP, Union Pacific and Gilead Sciences
Top Research Reports for Tesla, Visa & Exxon Mobil
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla (TSLA), Visa (V), and Exxon Mobil (XOM).
Will Jakafi's Performance Fuel Incyte's (INCY) Q1 Earnings?
by Zacks Equity Research
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports first-quarter 2021 results.
What's in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex's (VRTX) first-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and the company's pipeline progress.
What's in Store for Emergent (EBS) This Earnings Season?
by Zacks Equity Research
On Emergent's (EBS) upcoming first-quarter earnings call, investors are likely to focus on the company's update related to re-start of production at its Bayview facility.
Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) is set to provide updates on revenues and earnings when it releases first-quarter 2021 results on May 3.
Will Strong Veklury and HIV Sales Aid Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports first-quarter 2021 results.
Is a Beat in Store for CRISPR (CRSP) This Earnings Season?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) first-quarter earnings call, investor focus will be on updates of the company's progress with the development of its lead gene-editing candidate, CTX001.
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the first quarter is what remains to be seen when the company reports.
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.